Celldex Initiates Phase 2 Study of Barzolvolimab in Atopic Dermatitis
Go back to Celldex Initiates Phase 2 Study of Barzolvolimab in Atopic Dermatitis| CELLDEX THERAPEUTICS, Inc. (NASDAQ: CLDX) | Delayed: 41.71 +0.15 (0.36%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $41.56 | 52 Week High | $18.62 | |||
| Open | $41.87 | 52 Week Low | $2.85 | |||
| Day High | $42.92 | P/E | N/A | |||
| Day Low | $41.29 | EPS | $-1.02 | |||
| Volume | 808,913 | |||||
